About
The future of allergy care
We are Nectar and we are on a mission to put an end to allergies.
The time is now
120M Americans suffer from allergies and their associated diseases. It is the #1 chronic condition impacting Americans today and a leading cause of lost productivity for employers around the country.
Nectar’s comprehensive care is here to change that.
AMERICANS SUFFERING FROM ALLERGIES
120M
A passion for healthcare, for over a decade
Meet Ken Chahine, Founding CEO
Ken Chahine is a serial consumer healthcare entrepreneur. Prior to founding Nectar, Ken was the EVP and founding executive of AncestryDNA from 2011 to 2019. He grew the business from zero to $500+M ARR, successfully managed hyper-growth, and scaled the operations to over 11M genomic tests a year. Ken also founded AncestryHealth 2017, a DTC telehealth-based genomic predisposition test.
Prior to Ancestry, Ken was the CEO of Helio Health, a company focused on early cancer detection from a simple blood spot. He was also the CEO of Avigen, a gene therapy company focused on developing cures for hemophilia and other monogenic diseases.
Our team of industry professionals
We are a group of seasoned executives that have come together with a common purpose - putting an end to allergies. We champion science for good. And we’re here to change the world for good.
Vivian Arestia
Head of Marketing
Greg Burgess
Head of Engineering
Tsega Dinka
Head of Product
Shyam Joshi, M.D.
Head of Medical
Ben Oyler
Co-founder & Head of Business Ops
Hersh Patel
Co-Founder & Head of New Business
Our team of scientific and clinical experts
Our medical board of scientists and clinicians advise and oversee every aspect of our products, to ensure that we are only offering the best treatment that science has to offer.
Justin Greiwe, M.D.
Scientific Advisor
Kari Nadeau, M.D., PhD
Scientific Advisor
Mohamed Shamji, PhD
Scientific Advisor
John Zwetchkenbaum, M.D.
Scientific Advisor